Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a structural abnormality of hemoglobin called sickle hemoglobin (HbS). Clinical manifestations of SCD are mainly characterized by chronic hemolysis and acute vaso-occlusive crisis, which are responsible for severe acute and chronic organ damage. SCD is widespread in sub-Saharan Africa, in the Middle East, Indian subcontinent, and some Mediterranean regions. With voluntary population migrations, people harboring the HbS gene have spread globally. In 2006, the World Health Organization recognized hemoglobinopathies, including SCD, as a global public health problem and urged national health systems worldwide to design and establish programs for the prevention and management of SCD. Herein we describe the historical experience of the network of hemoglobinopathy centers and their approach to SCD in Italy, a country where hemoglobinopathies have a high prevalence and where SCD, associated with different genotypes including ß-thalassemia, is present in the native population.

Current challenges in the management of patients with sickle cell disease - A report of the Italian experience / Russo, G.; De Franceschi, L.; Colombatti, R.; Rigano, P.; Perrotta, S.; Voi, V.; Palazzi, G.; Fidone, C.; Quota, A.; Graziadei, G.; Pietrangelo, A.; Pinto, V.; Ruffo, G. B.; Sorrentino, F.; Venturelli, D.; Casale, M.; Ferrara, F.; Sainati, L.; Cappellini, M. D.; Piga, A.; Maggio, A.; Forni, G. L.. - In: ORPHANET JOURNAL OF RARE DISEASES. - ISSN 1750-1172. - 14:1(2019), pp. 120-120. [10.1186/s13023-019-1099-0]

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Powered by IRIS-about IRIS-Utilizzo dei cookie

 Copyright © 2022